Editas Medicine reports advancements in in vivo gene editing, financial results, and plans for upcoming development candidates by mid-2025. Editas Medicine, Inc. announced its progress in developing ...

The riches of gene therapy now include Casgevy, the recently approved ex vivo gene editing therapy. Many other riches await, and some of them are quite different from those within reach of traditional ...

Good morning, everyone, and thank you for joining Editas Medicine webinar to unveil our lead development candidate, EDIT-401. This webinar is being recorded and can be accessed in the future through ...

Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target. The positive ...

On Thursday, Editas Medicine Inc. (NASDAQ:EDIT) announced a strategic realignment to focus on in vivo gene editing. In vivo refers to studies or experiments conducted on living organisms or cells ...

Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...

Editas Medicine EDIT has nominated EDIT-401 as its lead in vivo development candidate. The experimental, one-time gene editing therapy is designed to significantly reduce LDL cholesterol (LDL-C) ...